Compare NetEase Inc (NTES) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Recursion Pharmaceuticals Inc — how do they compare? NetEase Inc trades at $134.95 (market cap $86.14B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: NetEase Inc is far larger — about 56.3× Recursion Pharmaceuticals Inc's market cap, and NetEase Inc pays a 2.25% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NTES | RXRX | |
|---|---|---|
Market Cap | $86.14B | $1.53B |
Sector | Media | Health |
52-Week High | $159.34 | $6.79 |
52-Week Low | $109.26 | $2.84 |
Enterprise Value | $62.61B | $946.50M |
Dividend Yield | 2.25% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
